My new Clinical Pipeline column is out in Nature Medicine.
It's on JAK inhibitors for alopecia - and at the black box safety warning the FDA attached to this entire class of drugs.

nature.com/articles/d41591-023

@cyrilpedia nice piece, and also informative. Had missed the black box warning on the whole JAK Stat family! Is the increased cardiovascular risk dose / time dependent, or is it idiosyncratic?

Follow

@gpollara I don't think we have enough data on that - the group that generated the warning (in another trial set) was oder and had a range of pre-existing conditions.

@cyrilpedia interesting. You can see how a signal came out in that population. My hunch is that it's time & dose dependent, but that doesn't massively help in autoimmune conditions in which treatment is long, spanning into years potentially.

Thank you.

@gpollara I agree completely - this is a lifelong treatment. I'm in NY right now and the advertisements for ruxolitinib are everywhere.

@cyrilpedia honestly, speaking from a UK perspective, the idea that (obviously non-generic) drugs are marketed straight to patients utterly bemusing!

Is the idea genuinely that the half-informed patient sees it and then goes to their doctor asking about/for it?!

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.